Ifosfamide associated myoclonus-encephalopathy syndrome

Area of Science:

• Neuro-oncology
• Clinical Neurology
• Pharmacology

Background:

• Ifosfamide is a chemotherapy agent with known central nervous system toxicity.
• Neurological adverse events, particularly encephalopathy, are common with ifosfamide.
• The occurrence and characteristics of movement disorders linked to ifosfamide toxicity are not well-documented.

Purpose of the Study:

• To investigate the incidence and types of movement disorders associated with ifosfamide toxicity.
• To characterize the clinical presentation and resolution of these movement disorders.
• To explore potential treatment options for ifosfamide-induced movement disorders.

Main Methods:

• Retrospective analysis of electronic medical records at Mayo Clinic (1997-2010).
• Identified patients treated with ifosfamide for systemic cancer.
• Screened for neurological complications, specifically movement disorders, following ifosfamide administration.

Main Results:

• Of 400 ifosfamide users, 52 had neurological complications; 7 (13%) exhibited movement disorders.
• Generalized myoclonus (4 patients) and postural tremor (3 patients) were the most common movement disorders.
• Movement disorders often co-occurred with encephalopathy and typically resolved spontaneously or with methylene blue treatment.

Conclusions:

• Movement disorders, including myoclonus and tremors, are potential neurological complications of ifosfamide toxicity.
• Encephalopathy remains the most frequent neurological adverse event.
• Methylene blue shows promise as an effective treatment for ameliorating ifosfamide-induced movement disorders.